Retail Clinics

  • McNeil recalls one lot of Tylenol

    FORT WASHINGTON, Pa. McNeil Consumer Healthcare has pulled a lot of Tylenol off the market, following complaints of a musty odor.

    McNeil said the uncharacteristic odor is thought to be caused by the presence of trace amounts of a chemical called 2,4,6-tribromoanisole. The lot of Tylenol 8-Hour, 50-count bottles are part of lot number BCM155 and carry the following UPC code: 3 0045-0297-51 8.

  • FDA approves Actavis' generic Ambien CR

    MORRISTOWN, N.J. The Food and Drug Administration has approved a drug for treating insomnia made by Actavis, the generic drug maker said Monday.

     

    Actavis announced the approval of zolpidem tartrate extended-release tablets in the 6.25-mg strength. The company has begun shipping the drug.

     

     

    The drug is a generic version of Sanofi-Aventis’ Ambien CR, which had sales of around $129 million during the 12-month period ended in June, according to IMS Health.

     

  • Dr. Reddy's to launch generic Prevacid

    HYDERABAD, India Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment.

    Dr. Reddy's lansoprazole delayed-release capsules will be available in 15-mg and 30-mg strengths, the drug maker said. The capsules are the generic version of Takeda's Prevacid delayed-release capsules.

    The FDA approved Dr. Reddy’s abbreviated new drug application for the drug on Oct. 15.

  • American Diabetes Association continues to raise awareness as celebratory month nears

    ALEXANDRIA, Va. American Diabetes Month will be celebrated this November, and the group leading the fight to end the disease is encouraging others to join the movement.

     

    Shortly after announcing that "Celebrity Apprentice" winner and Poison frontman Bret Michaels joined its "Stop Diabetes" movement, the American Diabetes Association has launched the "Share Your Vision to Stop Diabetes" video contest, and has asked Americans to:

  • Teva, Sandoz launch Prevacid SoluTab generics

    JERUSALEM The Food and Drug Administration granted approval for Teva's abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers.

    The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data.

    Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.

  • SymphonyIRI: Consumers turn to OTCs to curb healthcare costs

    CHICAGO Spurred by a difficult economy, over-the-counter medications increasingly are playing a dual role for consumers looking to minimize healthcare expenditures, the SymphonyIRI Group found in a new research paper titled “Over-the-Counter Medications: State of the Industry 2010” that was released last week.

     

  • Fera launches Garamycin

    NEW YORK Fera Pharmaceuticals has launched a preservative-free ointment for treating bacterial infections of the eye, the company said Monday.

     

    Fera said the launch of Garamycin (gentamicin sulfate) was to meet an unmet need for a preservative-free version of the drug. The Food and Drug Administration had received reports of allergic reactions in infants who had received formulations of the drug with preservatives.

     

     

  • APMA recommends Health Enterprises product for runners

    BETHESDA, Md. The American Podiatric Medical Association recently issued a series of recommendations for runners, including the use of a self-massager designed for post-athletic activities. Specifically, the association recommended Health Enterprises’ therapeutic hot-and-cold foot massager, a product that carries the APMA seal of approval.

     

  • Medco: Poor adherence may cause lack of response to medication

    BOSTON When a patient isn’t showing a response to a medication, a common tactic the doctor might use is to increase the dosage. According to a new study, however, the ineffectiveness might be happening because the patient isn’t properly taking the medication.

  • Study: Mediterranean diet may cut diabetes risk

    REUS, Spain New research has found a Mediterranean diet can cut the risk of developing Type 2 diabetes by 50% in nondiabetics with high cardiovascular risk.

    The study was conducted by Jordi Salas-Salvado and colleagues and published online in the Oct. 7 edition of Diabetes Care. This is the first randomized clinical trial to look specifically at use of the Mediterranean diet for the prevention of diabetes, the investigators said.

X
This ad will auto-close in 10 seconds